Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
| ▸ | MLYCD | O95822 | 7/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10159204 | 0.86 | HDAC3 (0.36) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL16716801 | 0.86 | HDAC3 (0.36) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL12252983 | 0.86 | HDAC3 (0.36) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL4600140 | 0.85 | TSHR (0.30) | — | |
| SCHEMBL4603004 | 0.85 | TSHR (0.30) | — | |
| SCHEMBL14980444 | 0.79 | MET (0.30) | — | |
| SCHEMBL29511396 | 0.78 | HDAC3 (0.41) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL18272940 | 0.77 | CTSK (0.38) | CTSK | |
| SCHEMBL23748718 | 0.76 | HDAC3 (0.37) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL23290002 | 0.75 | CYP2D6 (0.36) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012491-B2 | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140206648-A1 | HETEROCYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2013033461-A1 | HETEROCYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206648-A1 | HETEROCYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BCL6, BTD | HDAC3 1360/4885HDAC1 1802/4885HDAC2 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.